The first in a new class of treatment for endometriosis in Europe
A GnRH antagonist combined with add-back therapy in a single, once-daily pill1
Delivers pain relief for the majority of women with endometriosis2
Balances efficacy and safety1,2
Significant and sustained improvements in endometriosis pain and reduced impact of pain on daily life1,2
Comparable safety profile to placebo and BMD preserved1,2
Reduces use of analgesics, including opioids, with the majority of patients analgesic-free1,2
Provides adequate contraception after one month,1 with a mean time to ovulation of 23.5 days after cessation of treatment2